Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study: The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients

NCT00529633 is registered in ClinicalTrials.gov with George A. Kaysen, M.D. as lead sponsor.

NCT NCT00529633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00529633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study: The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients
Lead sponsor
George A. Kaysen, M.D.
Phase
Phase 3
Overall status
Terminated
Start date
September 30, 2007
Completion date
December 31, 2009
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypoalbuminemia